Personalised to support your treatment decisions

Find disease awareness content and supporting materials, including relevant drugs

Welcome:

Updates in your area
of interest

Articles your peers
are looking at

Bookmarks
saved

Days to your
next event

Learning Zones

Learning Zone

Advances in Lymphoma

1 mins

Learning Zone

THINK THROMBOSIS: Individualised care

1 mins

Learning Zone

Advances in HS

30 mins

Learning Zone

All Things Angioedema and Urticaria: Podcasts

30 mins

Learning Zone

Type 2 Inflammation in Upper & Lower Airway Diseases

1 mins

Learning Zone

Hidradenitis Suppurativa Academy

120 mins

Learning Zone

Ulcerative colitis Learning Zone

90 mins

Learning Zone

Psoriasis Academy

910 mins

Learning Zone

Myasthenia Gravis Learning Zone

110 mins

Learning Zone

Anti-CGRP therapies for migraine

85 mins

Learning Zone

Growth Hormone Deficiency

150 mins

Learning Zone

Alopecia areata Learning Zone

60 mins

Learning Zone

Weight Management in Type 2 Diabetes

90 mins

Learning Zone

Severe Asthma Learning Zone

100 mins

Learning Zone

mCRPC in focus

1 mins

Learning Zone

Complement-mediated kidney diseases

205 mins

Learning Zone

Type 2 Inflammation in Gastroenterology

160 mins

Learning Zone

Pompe Disease: Key findings from WMS 2022

150 mins

Learning Zone

Supportive care in oncology Learning Zone

150 mins

Learning Zone

Albumin in fluid management

115 mins

Learning Zone

Lipid management in ASCVD

215 mins

Learning Zone

Relapsing multiple sclerosis

115 mins

Learning Zone

Glaucoma Learning Zone

190 mins

Learning Zone

Antiplatelet therapy in ACS: Choices and Controversies

270 mins

Learning Zone

Chronic Kidney Disease Learning Zone

340 mins

Learning Zone

Hidradenitis suppurativa

220 mins

Learning Zone

Chronic Spontaneous Urticaria

1200 mins

Learning Zone

Multiple Sclerosis (MS) Learning Zone

160 mins

Learning Zone

Food Allergy Learning Zone

280 mins

Learning Zone

Lupus Learning Zone

240 mins

Webinars

Learning Zone

Anti-CGRPs in migraine management

60 mins

Learning Zone

Recurrence in early breast cancer

40 mins

Latest news

Drug news

Abbott initiates clinical study to evaluate the use of its deep brain stimulation system to manage severe depression.

Abbott announced it has initiated a pivotal clinical trial, called the TRANSCEND study, to evaluate the use of the company's deep brain stimulation (DBS) system to manage treatment-resistant depression (TRD), a form of major depressive disorder.

2 mins

Drug news

Positive results from phase III trial of Nucala (mepolizumab) announced in COPD.-GSK

GSK plc announced positive headline results of MATINEE, the phase III clinical trial evaluating Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5) in adults with chronic obstructive pulmonary disease (COPD).

1 min

Drug news

Full FDA approval for Filspari (sparsentan), the only non-immunosuppressive treatment that significantly slows kidney function decline in IgA nephropathy.- Travere Therapeutics

Travere Therapeutics, Inc., announced that the FDA has granted full approval to Filspari (sparsentan) to slow kidney function decline in adults with primary IgAN who are at risk of disease progression.

1 min

See all news